Specialty drugmakers poised for a game-changing outcome
Fidelity's Eddie Yoon says specialty drug manufacturers in the biotech industry with promising clinical data have the potential for blockbuster growth.
- Fidelity Portfolio Manager Eddie Yoon believes the stocks of certain specialty drugmakers have promising drug candidates in clinical trials, potentially setting them up for a healthy outlook and outsized growth.
- "Recently, I've been seeing a lot of 'green shoots' in some novel, viable drug candidates under study by biotechnology and specialty drug manufacturers, which gives me optimism about growth prospects for this innovation-driven segment of the health care sector," says Yoon, who manages Fidelity Advisor® Health Care Fund.
- In helming the sector-based, equity-focused strategy since 2008, Yoon leverages Fidelity's global health care team in building a broad portfolio of health care companies, ranging from high-quality, stable earnings growers to opportunistic names producing innovative products that disrupt the marketplace.
- As of March 31, the fund was notably overweight biotech stocks relative to the sector index, with sizable positions in a handful of specialty drugmakers. "Anti-obesity drugs may have taken center stage in 2024, but recent breakthroughs in biotech could be game-changers in the coming years," Yoon explains.
- In particular, Yoon is drawn to biotechs reporting needle-moving clinical data in blockbuster categories. These so-called specialty drugs, which typically are new drug categories that start at a higher price, have achieved recent sales growth of 15% to 17% per year, according to Yoon. In addition, he notes that biotech firms have been supported by a decrease in the cost of genome sequencing, the expansion of cell-based therapies and the accelerated pace of drug discovery.
- Yoon cites two companies, Alnylam Pharmaceuticals and Netherlands-based Argenx, as particularly well-positioned, both of which were among his largest holdings at the end of March.
- "Alnylam is a leader in RNA interference, a type of therapeutic that can 'silence,' or turn off, the production of specific genes that contribute to or cause a disease," Yoon says. "The company focuses on treating rare diseases and those with unmet medical needs, such as transthyretin amyloid cardiomyopathy, a potentially fatal heart ailment that occurs when faulty proteins build up in the heart."
- Argenx primarily develops antibody-based therapies for autoimmune conditions, including diseases causing muscle weaknesses. In 2024, the company benefited from robust sales of Vyvgart®, Argenx's flagship treatment for a rare autoimmune disorder in which a body's immune system attacks muscle cells, according to Yoon, who also notes the company released positive phase 2 trial results for Alkivia, its candidate for severe autoimmune diseases.
- Both Argenx and Alnylam have drug candidates that are fully funded into approval, Yoon says. "Within biotech, I focus on the most innovative assets in cell therapy, rare disease and immuno-oncology, and I believe these two companies have among the most promising growth prospects," Yoon concludes.
Fidelity Advisor Health Care Fund (FHCIX)
Seeks to provide capital appreciation.
Related insights
View all
For specific fund information such as standard performance and holdings, please go to the "Funds Managed" link on this page.
Investment decisions should be based on an individual’s own goals, time horizon, and tolerance for risk. Nothing in this content should be considered to be legal or tax advice, and you are encouraged to consult your own lawyer, accountant, or other advisor before making any financial decision. These materials are provided for informational purposes only and should not be used or construed as a recommendation of any security, sector, or investment strategy.
Fidelity does not provide legal or tax advice and the information provided herein is general in nature and should not be considered legal or tax advice. Consult with an attorney or a tax professional regarding your specific legal or tax situation.
Past performance and dividend rates are historical and do not guarantee future results.
Investing involves risk, including risk of loss.
Diversification does not ensure a profit or guarantee against loss.
Sector funds can be more volatile because of their narrow concentration in a specific industry. Growth stocks can perform differently from other types of stocks and the market as a whole and can be more volatile than other types of stocks. Value stocks can perform differently than other types of stocks and can continue to be undervalued by the market for long periods of time. • Stock markets, especially foreign markets, are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. • Foreign securities are subject to interest rate, currency exchange rate, economic, and political risks, all of which are magnified in emerging markets. • In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation, credit, and default risks for both issuers and counterparties. • Lower-quality bonds can be more volatile and have greater risk of default than higher-quality bonds. • The municipal market is volatile and can be significantly affected by adverse tax, legislative, or political changes, and the financial condition of the issuers of municipal securities. • The securities of smaller, less well-known companies can be more volatile than those of larger companies. • The funds can invest in securities that may have a leveraging effect (such as derivatives and forward-settling securities) that may increase market exposure, magnify investment risks, and cause losses to be realized more quickly. • Leverage can magnify the impact of adverse issuer, political, regulatory, market, or economic developments on a company. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Although the companies that the fund invests in may be highly leveraged, the fund itself does not use leverage as an investment strategy. Changes in real estate values or economic downturns can have a significant negative effect on issuers in the real estate industry. In the event of bankruptcy, a company’s creditors take precedence over the company’s stockholders. Third-party marks are the property of their respective owners; all other marks are the property of FMR LLC.